Latest in Analyst Clark Kellogg's
Sort by
144 items
-
Here’s why JPMorgan’s stock gets one analyst’s only downgrade after the Trump bank-stock rally
There’s only one other “deep value stock” among the large U.S. commercial and investment banks, according to one Oppenheimer analyst.Business - MarketWatch - November 20 -
‘New playbook’ on Wall Street powers Goldman Sachs price boost, says analyst
Citi’s Keith Horowitz flags already-lofty valuation for Goldman’s stock, but says it could go higher amid deal optimism.Business - MarketWatch - 6 days ago -
The world's auto giants will need to partner with Chinese companies to survive in China, analysts say
Time is running out for traditional foreign automakers to adapt to China's electric car market.Business - CNBC - 6 days ago -
MicroStrategy’s bitcoin buys lead to a new Wall Street-high stock price target
MicroStrategy buys more bitcoin, and Benchmark analyst’s new Street-high stock price target implies more than 60% upside.Business - MarketWatch - 2 days ago -
Snowflake’s stock advances on upgrade as AI ‘revolution’ hits its ‘next gear,’ one analyst says
Silicon Valley-based Snowflake is “in the sweet spot” to benefit from wider use of AI among businesses over the next 12 to 18 months, according to Wedbush analyst Dan Ives.Business - MarketWatch - 2 days ago -
Traders shouldn’t bet on another year of double-digit gains for U.S. stocks in 2025, analyst warns
Depending on how things shake out over the next few weeks, the S&P 500 could be on the cusp of a rare accomplishment: tallying a total return greater than 25% in two consecutive calendar years.Business - MarketWatch - 2 days ago -
Amgen’s stock closes off lows to avoid worst day in 24 years as weight-loss-drug data underwhelms
Amgen’s MariTide achieved up to 20% weight loss in a mid-stage trial, but analysts were expecting up to 25%.Business - MarketWatch - 18 hours ago -
Healthy Returns: Trump’s FDA pick Makary may be a relief for biotech and pharma, analysts say
Trump's FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.Business - CNBC - Yesterday -
Manchester United’s turnaround is in early stages, but will pay off in long term, says analyst
Manchester United, which reported fiscal first-quarter results Tuesday, remains in the early stages of its turnaround, according to analyst firm Jefferies.Business - MarketWatch - Yesterday -
Technical analyst DeMark says his models are flagging major caution for the holiday week
Markets have often changed their trend around holidays, and one widely followed technical analyst says that shift may happen again.Business - MarketWatch - 20 hours ago -
IMAX’s stock is up more than 70% this year. Here’s why an analyst sees more room to run.
IMAX Corp.’s shares have climbed 71.2% in 2024, and analyst firm Wedbush sees more upside ahead for the high-end movie-theater operator.Business - MarketWatch - 15 hours ago -
Urban Outfitters’ stock on track for biggest gain in more than a year, as analysts sense a shift in tone
Urban Outfitters’ stock soared 14% Wednesday to put it on track for its biggest one-day gain in more than a year, as analysts weighed in on better-than-expected third-quarter earnings and ...Business - MarketWatch - 14 hours ago -
Fever's Caitlin Clark shares main goal for pro-am round: 'I just don't want to hit anyone with a golf ball'
The WNBA's Rookie of the Year is participating The ANNIKA on WednesdaySports - CBS Sports - November 13